Adam Bruce comes with a background in product innovation and entrepreneurship. He’s been instrumental in establishing TikoMed, a company with now two projects in Phase 2 clinical development for neurology and cell therapy. During his time at TikoMed he has served in positions as CEO, Chairman, Business Development, and project VP. Over the years Adam has provided advice on financing and strategic development in various constellations for life science and med-tech companies. Adam holds a business degree from Lund University.

Professor Emeritus
Lund University
University of Geneva

Claes Wollheim is a qualified Swedish physician and an international authority on beta-cell biology and diabetes research. He has dedicated almost five decades to preclinical diabetes research, focusing on the hormones secreted from the islets of Langerhans changing the view of diabetes from a disease dominated by insulin resistance to one in which beta-cell dysfunction is also central. He received numerous scientific distinctions, including the Claude Bernard Prize of the European Association for the Study of Diabetes (EASD), honorary doctor degrees (Doctor Honoris Causa) of Semmelweis University, Budapest and Lund University as well as an elected member of the Swiss Academia of Medical Sciences and Academia Europaea.

Jan Alenfall earned his doctorate in tumor pharmacology and biology from Lund University in 1995. With over 25 years of pharmaceutical R&D experience, he has authored more than 20 scientific papers and holds multiple pending patents. Early in his career, he focused on innovative treatments for immunological disorders and cancer, working on clinical trials in immunology and oncology at Pharmacia & Upjohn.

In 2013, he became Managing Director of Follicum AB, which developed peptide-based drugs for various indications, including diabetes, before it was transitioned to Coegin Pharma. Jan specializes in early-stage pharmaceutical development, business planning, risk assessment, and the design and execution of preclinical and clinical studies, demonstrating a strong research focus and goal-driven leadership.

Currently, Jan is the CEO of Callipa AB, his consulting company, and Edvince AB, a company involved in treatment for stroke.

Yingying Ye has a background in Endocrinology and Metabolism with PhD from Lund University and Postdoc experience at Stanford University.